• Developing first-in-class therapeutics to leverage the benefits of omega-3 fatty acid metabolites
  • Our lead candidate OMT-28 will enter Phase II clinical development, soon
  • Out of 174 initial applications, OMEICOS reached the final shortlist of 10 companies.

Novel therapeutic strategy


OMEICOS Therapeutics’ is focused on developing therapeutics that can be broadly deployed in inflammatory, cardiovascular, ophthalmology and other disease indications using its proprietary technology and extensive knowledge of omega-3 fatty acid metabolism and biology. Learn more

Our pipeline of small molecules are first-in-class synthetic analogs of omega-3 fatty acid-derived metabolites that show up to 1,000-fold higher biological activity and significant improvement in pharmacokinetic properties compared to their natural counterparts. 

Phase I clinical trial has been completed. More details please see: Phase I clinical trial 

The randomized, double-blind, placebo-controlled Phase I study revealed an excellent safety and tolerability profile for OMEICOS' lead candidate OMT-28. 


icon herz

Cardiovascular Diseases 

Our lead candidate, OMT-28, is in clinical development to achieve long-term heart rhythm control in atrial fibrillation

Learn more

icon auge


 Our ophthalmology program targets ocular diseases and is developed through our US subsidiary, OMEICOS Ophthalmics

Learn more

Follow us


Meet us

Heart Rhythm 2019, San Francisco

Contact us

contact g kl